Skip to main content
ZBIO
NASDAQ Life Sciences

Zenas BioPharma Reports Positive Phase 3 INDIGO Open-Label Extension Data for Obexelimab in IgG4-RD

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$26.4
Mkt Cap
$1.721B
52W Low
$13.5
52W High
$44.6
52W Position info
96% above low
Off High info
41% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

ZBIO sits 96% above its 52-week low of $13.5.

Summary

Zenas BioPharma announced new Phase 3 INDIGO open-label extension data showing sustained flare protection and reduced glucocorticoid toxicity for obexelimab in IgG4-RD, plus positive vaccine response sub-study results.


Key Events · Product Development and Regulatory · ZBIO

  • Phase 3 INDIGO Open-Label Extension Data

    12-month flare-free probability of 0.93 (adjudicated) and 0.87 (investigator-determined) for obexelimab in IgG4-RD; median cumulative glucocorticoid rescue dose was 0 mg.

  • Reduced Glucocorticoid Toxicity

    Obexelimab significantly reduced cumulative glucocorticoid toxicity vs placebo at week 52 (GTI Cumulative Worsening Score difference: -11.4; p=0.021).

  • Vaccine Response Sub-Study

    Vaccination during a treatment-free window produced seroimmunity to influenza in 86% and COVID-19 in 100% of participants, with no disease flares observed.

  • Regulatory Context

    Data add to the clinical evidence supporting obexelimab's BLA for IgG4-RD, which the FDA accepted in August 2026.


Analysis · ZBIO · Life Sciences

New Phase 3 INDIGO open-label extension data show obexelimab sustained flare protection over 12 months, with a 0.93 probability of remaining flare-free based on adjudicated flares. The drug also significantly reduced cumulative glucocorticoid toxicity versus placebo (GTI score difference -11.4, p=0.021), and a vaccine sub-study showed preserved immune responses during a treatment-free window. These results strengthen the case for obexelimab as a long-term, steroid-sparing therapy for IgG4-RD, a chronic disease affecting an estimated 25,000 U.S. patients. The data arrive as the company awaits FDA action on its BLA for obexelimab in IgG4-RD, accepted in August 2026, and ahead of Phase 2 SunStone topline results in SLE expected in Q4 2026.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ZBIO was trading at $26.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $13.50 to $44.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ZBIO - Latest Insights

ZBIO
Nov 05, 2026, 7:19 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $28.46
Real-time Price: $26.00 info
Change: -$2.46 (-9%) info
Market Cap: $1.792B info
ZBIO
Nov 05, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $28.46
Real-time Price: $26.00 info
Change: -$2.46 (-9%) info
Market Cap: $1.792B info
ZBIO
Aug 19, 2026, 4:15 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $31.04
Real-time Price: $26.00 info
Change: -$5.04 (-16%) info
Market Cap: $1.792B info
ZBIO
Aug 13, 2026, 7:15 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $31.30
Real-time Price: $26.00 info
Change: -$5.30 (-17%) info
Market Cap: $1.792B info
ZBIO
Aug 13, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $31.30
Real-time Price: $26.00 info
Change: -$5.30 (-17%) info
Market Cap: $1.792B info